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Abstract
Background: Microvascular complications, including retinopathy and nephropathy are seen with type 1 diabetes. It is 
unknown whether functional changes in aqueous humor flow or intraocular pressure (IOP) develop in parallel with 
these complications. This study was designed to test the hypothesis that clinical markers of microvascular 
complications coexist with the alteration in aqueous humor flow and IOP.
Methods: Ten patients with type 1 diabetes and ten healthy age- and weight-matched controls were studied. 
Aqueous flow was measured by fluorophotometry during a hyperinsulinemic-euglycemic clamp (insulin 2 mU/kg/
min). Intraocular pressure was measured by tonometry at -10, 90 and 240 minutes from the start of the clamp, and 
outflow facility was measured by tonography at 240 minutes.
Results: During conditions of identical glucose and insulin concentrations, mean aqueous flow was lower by 0.58 μl/
min in the diabetes group compared to controls (2.58 ± 0.65 versus 3.16 ± 0.66 μl/min, respectively, mean ± SD, p = 
0.07) but statistical significance was not reached. Before the clamp, IOP was higher in the diabetes group (22.6 ± 3.0 
mm Hg) than in the control group (19.3 ± 1.8 mm Hg, p = 0.01) but at 90 minutes into the clamp, and for the remainder 
of the study, IOP was reduced in the diabetes group to the level of the control group. Ocular pulse amplitude and 
outflow facility were not different between groups. Systolic blood pressure was significantly higher in the diabetes 
group, but diastolic and mean arterial pressures were not different.
Conclusions: We conclude that compared to healthy participants, patients with type 1 diabetes having 
microalbuminuria and retinopathy have higher IOPs that are normalized by hyperinsulinemia. During the clamp, a 
reduction in aqueous flow was not statistically significant.
Background
Maintenance of intraocular pressure (IOP) within a nar-
row range is essential for the normal health of the eye.
The IOP is kept within these limits by the production rate
of aqueous humor into the posterior chamber of the eye
and its drainage out of the anterior chamber angle. The
production rate can be assessed by measuring the aque-
ous flow rate from the posterior chamber into the ante-
rior chamber. In addition to contributing to the
maintenance of IOP, the flow of aqueous humor delivers
nourishment to and removes waste products from the
avascular structures within the anterior segment [1].
Thus, adequate aqueous flow is crucial for the health of
the eye. Alterations in aqueous flow have been described
in humans with diabetes, and it is thought that this con-
tributes to diabetes-related changes in the eye. It is
unclear whether the alterations have functional conse-
quences or reflect major pathophysiologic processes
associated with diabetes-related eye disease [2-4].
We previously reported that aqueous flow was
decreased by 15% in patients with type 1 diabetes without
evidence of microvascular complications, compared to
healthy control participants [3]. Measurements were
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made under rigorous conditions utilizing a hyperinsu-
linemic-euglycemic clamp. Such conditions were neces-
sary to control insulin and glucose concentrations in both
study groups during the measurements, as these factors
could impact vascular blood flow, an important determi-
na n t o f  a qu eo us  fl ow [5-7 ] .  If  not  ca r efu lly  c on tr ol led,
insulin and glucose potentially could affect aqueous flow
and mask or mute effects due to the diabetes. Other pub-
lished studies did not control for the levels of insulin and
glucose during the assessment of aqueous flow [2,4,6]
making it difficult to separate the disease effect from the
effect of insulin and glucose.
Severity of diabetic retinopathy is related to length and
magnitude of exposure to hyperglycemia [8-10]. Diabetic
retinopathy appears to exist concurrently with microvas-
cular abnormalities in the kidney and signals diabetic
nephropathy [11]. If a decrease in aqueous flow accompa-
nies diabetic retinopathy, and if these changes are related
by common pathophysiologic mechanisms, it is hypothe-
sized that patients with evidence of retinopathy will have
decreased aqueous flow that could impact IOP. The rela-
tionship between rate of aqueous flow and the severity of
complications in the eyes of patients with diabetes is not
known. This study examines aqueous flow under condi-
tions of hyperinsulinemia and euglycemia in eyes of
patients with type 1 diabetes with evidence of retinopathy
and microalbuminuria and eyes of healthy non-diabetic
age-matched controls. This differs from our previous
study that measured aqueous flow in patients with type 1
diabetes but without microvascular complications [3].
Accompanying the measurement of aqueous flow were
assessments of other parameters that may be affected by
the disease, including IOP, outflow facility, and blood
pressure.
Methods
Ten patients with type 1 diabetes from the diabetes clin-
ics at the University of Nebraska Medical Center and ten
healthy, age-matched non-diabetic control participants
from the general population were enrolled in this one-
day, cross-sectional study. All studies were performed in
the Clinical Research Center at the University of
Nebraska Medical Center. The protocol was approved by
the Institutional Review Board at the University of
Nebraska Medical Center.
Inclusion criteria for patients with type 1 diabetes were
a diagnosis of type 1 diabetes by ADA criteria [12] for at
least 10 years and the presence of both microalbuminuria
and retinopathy. Microalbuminuria was defined as ≥ 30
mcg/mg creatinine on a random urine specimen at
screening, or treatment with an angiotensin converting
enzyme (ACE) inhibitor or angiotensin receptor antago-
nist (ARB) for the presence of a previously elevated albu-
min excretion [13]. In all patients on ACE inhibitors or
ARBs, the medical record substantiated a previously ele-
vated albumin excretion rate of > 30 mcg/mg/cr on more
than one occasion. Retinopathy was identified by a single
ophthalmologist (EM) using the Early Treatment Dia-
betic Retinopathy Study Final Scale of Diabetic Retinopa-
thy Severity for Individual Eyes [14]. Patients with
diabetes could not have an HgbA1c > 12%, history of laser
treatment to the retina, or an insulin dose > 100 units per
day.
Exclusions for both groups were coronary artery dis-
ease, heart failure, cancer, AIDS, obstructive lung disease,
or other chronic major medical problems, body mass
index (BMI) > 30 mg/m2, anemia (hemoglobin < 11.5 g/dl
for women and < 13.0 g/dl for men), serum creatinine >
2.0 mg/dl, a history of cigarette smoking within the previ-
ous three months, a history of alcohol intake > 2 ounces
per day on a chronic basis, pregnancy, a history of trans-
plantation, cornea defects, hypersensitivity to fluores-
cein, an ocular infection or inflammation or use of ocular
drugs within the previous three months, a history of ocu-
lar surgery, or any medication that could affect IOP.
Healthy participants could have no evidence of diabetes
at screening and all participants were at least 19 years of
age.
After informed consent was obtained, participants
underwent a medical history, physical examination,
screening laboratory tests, and a screening eye examina-
tion. Screening laboratory tests included hemoglobin,
fasting plasma glucose, serum creatinine, and a random
urine for microalbumin/creatinine ratio. Screening eye
exams included visual acuity, pachymetry, tonometry, a
slit-lamp examination, and a dilated fundus examination
for retinopathy grading.
Three days prior to their clamp study, patients with
type 1 diabetes were changed to NPH insulin for their
basal insulin. On the night prior to the study, patients
with type 1 diabetes were admitted to the hospital to
receive intravenous regular insulin designed to maintain
plasma glucose between 70-140 mg/dl. This prevented
large fluctuations in plasma glucose levels for twelve
hours before measurements commenced. The last dose of
NPH insulin was given on the morning before admission.
At 2:00 AM, all participants received 8 drops of fluores-
cein 2% in each eye with a five-minute interval between
drops.
On the day of the study, all participants were admitted
to the Clinical Research Center at the University of
Nebraska Medical Center following an overnight fast.
Both groups were studied using a hyperinsulinemic-eug-
lycemic glucose clamp [15]. Insulin and glucose were
infused at controlled rates using Harvard pumps (Model
22 Multi; Harvard Bioscience, Holliston, MA). Insulin
was infused at a constant rate of 2 mU/kg/min (Humulin®,
Eli Lilly, Co. Indianapolis, IN), and glucose was variablyLane et al. BMC Ophthalmology 2010, 10:19
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infused to maintain plasma glucose at 90 mg/dl. The
hand used to sample arterialized venous blood was
placed in a hot box maintained at 60°C for the duration of
the study. Potassium phosphate (30 meq in 250 cc saline
0.45%) was infused at 30 ml/hr during the clamp proce-
dure.
Aqueous flow was measured using the intracameral flu-
orescein dilution technique, as quantified by a Fluorotron
Master fluorophotometer (Ocumetrics, Palo Alto, CA)
[16]. Anterior chamber volume was calculated from ante-
rior chamber depth and corneal thickness measurements
collected during screening. The amount of fluorescein in
the cornea and anterior chamber was measured at -10
and +90 minutes from the start of the clamp and every 45
minutes thereafter for 4.5 hours. The clamp procedure
commenced at zero minutes. Aqueous flow was deter-
mined as described previously [16,17].
Intraocular pressure was measured at -10 minutes, +90
minutes, and +4.5 hours using a pneumatonometer
(Reichert Ophthalmic Instruments, Depew, NY). Two
readings of each eye were made and averaged. Ocular
pulse amplitude was obtained from the pressure wave. A
two-minute tonography measurement (tonography set-
ting on the Classic 30 pneumatonometer, Reichert Oph-
thalmic Instruments, Depew, NY) was performed on
each eye at +4.5 hours for determination of outflow facil-
ity [18].
Analyses of hemoglobin A1c, serum creatinine, and
urine albumin and creatinine were performed in The
Nebraska Medical Center's Clinical Laboratory using
standard methods. Hemoglobin A1c was measured using
high-pressure liquid chromatography (normal range: 4.0-
6.0%). Urine albumin was measured by nephelometry.
During the clamp procedure, plasma glucose was mea-
sured every five minutes using a glucose oxidase method
(Glucose Analyzer II; Beckman, F ullerton, CA). Plasma
insulin levels were measured by radioimmunoassay
(Linco Research, Inc, St. Louis, MO) with 0.2% cross-
reactivity with proinsulin and a sensitivity of 12 pmol/l.
The inter-assay and intra-assay coefficients of variation
were 7.9% and 2.5%, respectively.
The glucose infusion rate during the final 30 minutes of
the clamp was used to compare insulin sensitivity
between groups [19]. Mean arterial pressure (MAP) was
calculated using the formula: MAP = [SBP + (2 × DBP)]/
3, where SBP is systolic blood pressure and DBP is dia-
stolic blood pressure.
Baseline characteristics were compared between con-
trol and diabetic participants using a non-parametric
W i l c o x o n  r a n k  s u m  t es t  f o r  c o n t i n u o us  m eas u r e s  o r  a
Fisher's exact test for categorical measures. Changes in
the eye-level outcome measures over time were com-
pared between the normal and diabetic participants using
a nested mixed effects ANOVA model. The ANOVA
model was fit using right and left eye data (combined)
where the correlation within a participant was accounted
for using a random participant effect nested within diabe-
tes status. The model also included a fixed diabetes status
term, a fixed time term, and the interaction between time
and diabetes status. Natural log transformations of the
response were modeled when necessary to meet ANOVA
modeling assumptions. Pair-wise comparisons among
time points were made using a Tukey's adjustment. Given
the limited sample sizes, a simplified sensitivity analysis
approach was used where changes over time were calcu-
lated using the mean of right and left eye data and com-
parisons made between diabetic and non-diabetic
participants using a non-parametric Wilcoxon rank sum
test. Results of this simplified approach were similar to
results from the mixed effect ANOVA modeling
approach and are therefore not presented. Descriptive
statistics are based on the average of right and left eye
measurements and all descriptive results are expressed as
means ± standard deviation (SD).
Based on our previous study [3], we calculated that a
sample size of 10 participants per group would be needed
to detect a difference between a mean aqueous flow value
of 2.4 μl/min for the diabetes group and 3.2 μl/min for the
control group with 80% power assuming a common stan-
dard deviation of 0.7 ml/min, a 2-sided 0.05 alpha level
and a correlation coefficient of 0.7 between the right and
left eyes of each participant [20].
Results
A total of 20 participants (10 patients with type 1 diabetes
and 10 healthy controls) were studied. Participants were
similar in age, gender, ethnicity, body mass index, dia-
stolic blood pressure, mean arterial blood pressure, and
serum creatinine (Table 1). Patients with type 1 diabetes
had higher systolic blood pressure (119 ± 14 versus 105 ±
9 mm Hg, p = 0.04), although mean arterial pressure was
not different between groups. As expected, the patients
with diabetes had higher HbA1c levels, compared to
healthy controls. The patients had type 1 diabetes for a
mean of 25 years.
By design, the patients with diabetes had higher albu-
min excretion rates, as determined by a random urine for
albumin to creatinine ratio. The mean albumin excretion
rate was in the macroalbumin range, but the median
value of 16.9 mcg/mg creatinine was not.
Retinopathy was present in all 10 patients with diabe-
tes. One participant had retinopathy grade 1 in the right
eye and no retinopathy in the left eye. For this patient,
only the eye with retinopathy was used in the data analy-
sis. Seven participants had retinopathy grades of 1 for
both eyes. One participant had retinopathy grade 2 in the
right eye and 3 in the left. One participant had retinopa-Lane et al. BMC Ophthalmology 2010, 10:19
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thy grade 4 in the right eye and 3 in the left. All control
participants had no retinopathy.
The insulin and glucose levels during the euglycemic-
hyperinsulinemic glucose clamp are summarized in Fig-
ure 1. At baseline, mean total insulin levels were signifi-
cantly greater for patients with diabetes, compared to
controls (p < 0.001). Within one hour, insulin concentra-
tions were similar between groups and remained that way
for the remaining 3.5 hours. Insulin concentrations dur-
ing the last hour of the clamp were similar (174.1 ± 30.6
mU/ml in patients versus 166.8 ± 33.9 mU/ml in controls,
p = 0.6). Glucose concentrations at the beginning of the
clamp were higher in patients with type 1 diabetes, com-
pared to controls. By 80 minutes into the clamp the glu-
cose levels were similar between groups and remained
similar for the rest of the clamp. The whole body glucose
infusion rate during the last 30 minutes of the clamp, an
indication of insulin sensitivity, was lower in patients with
type 1 diabetes, compared to controls (7.6 ± 3.7, versus
11.7 ± 2.9 mg/kg/min, respectively, p = 0.01).
The mean aqueous flow rate in patients with type 1 dia-
betes was decreased compared to healthy controls,
although this decrease did not reach statistical signifi-
cance (p = 0.07). The baseline IOP was significantly
higher in the patients with diabetes compared to controls.
Using a mixed effects ANOVA model, the IOP in the dia-
betes group decreased over time, whereas the IOP in the
control group remained unchanged (p = 0.03). Within the
diabetes group, the IOP decrease over time occurred
between +0 and +90 minutes with no further change
between +90 and +240 minutes. Mean tonographic out-
flow facility at 240 minutes into the clamp was similar
Table 1: Participant Characteristics
Characteristics Groups P-Value*
Type 1 Diabetes
(n = 10)
Controls
(n = 10)
Age (years) 35.2 (12.5) 34.9 (9.4) > 0.9
Female 4 (40%) 5 (50%) > 0.9
Ethnicity > 0.9
Caucasian 8 (80%) 8 (80%)
African American 2 (20%) 1 (10%)
Asian American 1 (10%)
Height (cm) 170.4 (10.9) 171.2 (10.7) 0.7
Weight (kg) 76.9 (15.5) 83.4 (35.3) 0.9
BMI (kg/m2) 26.3 (4.3) 24.6 (2.7) 0.8
Duration of diabetes (yrs) 25.4 (8.4) N/A
Systolic BP (mm Hg) 119 (14) 105(9) 0.04
Diastolic BP (mm Hg) 71 (10) 65 (5) 0.2
Mean arterial BP (mm Hg) 87 (11) 79 (5) 0.1
HbA1c (%) 9.1 (2.2) 5.1 (0.3) 0.001
S creatinine (mg/dl) 1.0 (0.3) 1.0 (0.1) 0.5
Urine microalbumin (μg/mg cr) 367.4 (668.7)
Median = 16.9
4.32 (1.5)
Median = 3.9
0.005
Results are mean ± (SD), unless otherwise noted
*P value by Wilcoxon rank sum test or Fisher's exact test
N/A, not applicableLane et al. BMC Ophthalmology 2010, 10:19
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between the two groups. A summary of these results are
found in Table 2.
Discussion
In the present study, the 19% decrease in aqueous flow in
the diabetes group with microvascular complications
compared to the control group, was similar in magnitude
to our previous study of patients with type 1 diabetes and
no complications (15%) [3]. A finding in the earlier study
that aqueous flow was slowed, despite no diabetic com-
plications, led us to hypothesize that aqueous flow is
slowed even further in the presence of complications.
This did not prove to be the case. It is possible that the
complications were sufficiently minor and the standard
diabetes treatments sufficiently effective that aqueous
flow was not reduced further in the presence of mild
microvascular complications. By design, our participants
exhibited only mild evidence of microvascular complica-
tions in the retina (retinopathy grade of 1 in seven of the
ten patients) and kidney (microalbunimuria in all
patients).
Another consideration for the lack of a greater decline
in aqueous flow than expected is the use of ACE inhibi-
tors in all patients with type 1 diabetes in this study. This
is standard care for patients with microalbuminuria.
These drugs are known to prevent thickening of the
g l o m e r u l a r  b a s e m e n t  m e m b r a n e  i n  d i a b e t i c  r a t s  [ 2 1 ] .
ACE inhibitors might protect the basement membrane of
the ciliary body in a similar manner and protect against
diabetes-related changes in aqueous production. A study
in normal rabbits reported that topical ACE inhibitors
reduced IOP and aqueous flow [22]. Unlike the rabbit
study, our study did not find reduced IOP in the diabetes
group. In fact, IOP before the clamp procedure was
higher in the diabetes group, compared to the control
group, suggesting that the ACE inhibitors were not pre-
scribed at a dose sufficient to maintain IOP within nor-
mal levels. Hence, the aqueous flow effect was more likely
due to the diabetes than the ACE inhibitor.
It remains to be seen whether aqueous flow decreases
further with advanced diabetic retinopathy. This would
be a difficult study to design as most patients with
advanced retinopathy are treated with laser photocoagu-
lation which can affect the measurement of aqueous flow.
Laser treatments to the eye may cause chronic low-grade
inflammation, and the flare and cells in the anterior
chamber might interfere with the measurement of intrac-
ameral fluorescein used in the determination of aqueous
flow [23].
Previous studies [2,4] have reported decreased aqueous
flow in patients with diabetes who did not undergo a
hyperinsulinemic-euglycemic clamp. Compared to
healthy controls, patients with type 1 diabetes are more
insulin resistant and are exposed to higher insulin con-
centrations [3]. As insulin and glucose levels are known
to have an effect on blood flow in tissues [5-7] and blood
flow is a determinant of aqueous flow [1,24], we per-
formed a hyperinsulinemic-euglycemic glucose clamp to
obtain similar insulin and glucose levels between groups
during the time of the aqueous flow measurements. The
insulin levels were purposefully kept in the upper range
of the dose-response curve for insulin to suppress hepatic
glucose production and allow the glucose infusion rate to
Figure 1 Glucose and insulin concentrations (mean ± SD) over time during the hyperinsulinemic-euglycemic glucose clamp in patients 
with type 1 diabetes and age-matched healthy controls (n = 10).Lane et al. BMC Ophthalmology 2010, 10:19
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equal total body glucose utilization, an indication of insu-
lin sensitivity.
Our study has several limitations of note. First, due to
the complexity of the measurement methods and the dif-
ficulty in finding appropriate and willing participants, it is
a small study with limited power. Prior to the study start a
power analysis indicated that the numbers enrolled
would be sufficient to detect expected statistically signifi-
cant differences in aqueous flow. However, this did not
happen. Also, observed effect sizes for secondary end-
points, including intraocular pressure and outflow, were
smaller than the assumed standardized effect size for
aqueous flow, resulting in less than 80% power to address
these endpoints. Second, the design of the study only
allows us to examine acute ocular changes during specific
conditions of insulin and glucose concentrations.
Although patients with diabetes were selected based on
their burden of microvascular complications, there was
no control for long-term exposure to hyperglycemia prior
to the study start. Finally, the insulin concentrations dur-
ing the clamp studies were higher than those experienced
during daily living. Results may have been different under
different experimental conditions.
Two important findings in our study were that systolic
pressure and IOP were significantly greater in patients
with type 1 diabetes compared to healthy controls. This
agrees with several recent epidemiologic studies that
report an association between systolic pressure and ele-
vated IOP [25-28] and association between diabetes and
elevated IOP [26,29,30]. It has been reported recently that
diabetic patients have lower corneal hysteresis than
healthy controls, which could explain, in part, the higher
IOPs in this group [31-34]. Further research in this area
would be of interest. Diabetes is not always associated
with elevated IOP [3,35], but if it is found, it could be
explained in part by higher insulin resistance [36] and
chronic hyperglycemia [37]. Since insulin acts as a vaso-
dilator through nitric oxide in the eye, there may be some
common effect between insulin and IOP [38]. It has been
shown that nitric oxide decreases IOP acutely by increas-
ing trabecular outflow facility [39,40]. It has been postu-
lated that IOP falls acutely in response to nitric oxide-
induced contraction of cell volume through such media-
tors as soluble guanylate cyclase, protein kinase G, and
the large-conductance Ca2+ -activated K+ channel [41]. In
fact, these regulatory elements may associate insulin with
changes in outflow facility. Why the patients with type 1
diabetes had a greater response to acute insulin, com-
pared to controls, may be because of the presence of gen-
eralized insulin resistance.
The rapid IOP fall in patients with type 1 diabetes in
response to intravenous insulin is a novel finding. This is
the period of equilibration of insulin in the peripheral tis-
sues. The IOP reduction during this time may have been
in response to the increase in circulating insulin levels,
which may have had the effect of overcoming any insulin
resistance, especially on local blood flow. After the first
ninety minutes and for the duration of the study, there
was no difference in IOP between groups. Patients with
relatively well-controlled type 1 diabetes in which retinal
blood flow was measured by laser Doppler flowmetry
with minimal background retinopathy were similar to
control participants [42]. Most studies characterizing the
effect of insulin on IOP and ocular fluid dynamics have
reported averages over many hours to days. Rapid fluctu-
ations in glucose and insulin concentrations apparently
Table 2: Aqueous flow, outflow facility and IOP in patients with type 1 diabetes and healthy age-matched controls
Measurement Type 1 Diabetes
(n = 10)
Controls
(n = 10)
P-Value*
Aqueous flow (μl/min) 2.58 ± 0.65 3.16 ± 0.66 0.07
IOP, +0 min (mmHg) 22.6 ± 3.0 19.3 ± 1.8 0.01
IOP, +90 min (mmHg) 20.1 ± 3.6 19.3 ± 2.5 0.6
IOP, +240 min (mmHg) 21.1 ± 3.1 19.1 ± 1.9 0.1
Outflow facility (μl/min/mmHg) 0.32 ± 0.10 0.32 ± 0.09 0.98
Results are mean ± (SD) unless otherwise indicated.
IOP, intraocular pressure
IOP, 0 is the measurement just before the glucose clamp began.
IOP, +90 is the IOP at ninety minutes into the clamp
IOP, +240 is the IOP at the end of the clamp procedure.
*comparing type 1 diabetes with controls by ANOVALane et al. BMC Ophthalmology 2010, 10:19
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can affect IOP acutely. Rapid reductions in blood flow
sufficient to slow aqueous flow and hence, reduce IOP,
could explain these findings. Even with rigorous glucose
control, patients with type 1 diabetes often experience
insulin and glucose fluctuations that apparently affect
IOP. The implications for normal physiology and disease
a s  t h e y  r e l a t e  t o  t h e  f r e q u e n c y  a n d  a m p l i t u d e  o f  I O P
changes over time could be significant.
An additional finding of interest in the current study is
the normal IOP in the diabetes group during the clamp
despite the presence of reduced aqueous flow. If all other
parameters of aqueous humor dynamics remained
unchanged, a reduction in aqueous flow alone should
reduce IOP. Since this did not happen, other changes in
aqueous humor dynamics may be occurring concurrent
to the slowed aqueous flow. Such changes could include
an increase in episcleral venous pressure, reduction in
trabecular outflow facility, or reduction in uveoscleral
outflow. Outflow facility was not different between
groups when measured by two-minute tonography in our
study and another [4]. A reduction in episcleral venous
pressure is possible, reflecting acute effects on blood
flow. Ocular pulse amplitude was not changed by diabe-
tes or insulin in our study which agrees with another
study of patients with diabetes who were not subjected to
the glucose clamp [43]. This implies that choroidal perfu-
sion and ocular blood flow remain normal in these
patients. A reduction in uveoscleral outflow is the likely
explanation for the normal IOP despite a reduction in
aqueous flow. This possibility is not without some evi-
dence. A number of tissues demonstrate increased matrix
deposition and basement membrane thickening in
response to short- and long-term hyperglycemia [44-47].
In cr eased m a trix deposi ti on has  bee n ide n t ifi ed i n t he
ciliary muscle (site of uveoscleral outflow) of aging rhesus
monkeys when compared to young monkeys [48,49].
Uveoscleral outflow is reduced with age in humans [50]
which may be related to excessive buildup of matrix
material over decades. Therefore, in diabetes, there could
be an association between the rate of uveoscleral outflow
and matrix deposition in diabetes.
Conclusions
Patients with type 1 diabetes, having microalbuminuria
and diabetic retinopathy, had IOPs and baseline systolic
blood pressures that were higher than healthy controls.
During the performance of a hyperinsulinemic-euglyce-
mic glucose clamp when insulin and glucose levels were
similar between groups, IOP was reduced to control lev-
els. Aqueous flow rate over the entire clamp period
trended lower in the diabetes group but was not statisti-
cally significant, while outflow facility remained
unchanged. Further studies under controlled conditions
in more advanced diabetic retinopathy are required to
determine if major alterations in aqueous flow are mani-
fest.
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